FindTrial
Sign In

ASSESSMENT OF ALTERED TEMPERAMENT IN THE PATIENTS OF NON ALCOHOLIC FATTY LIVER DISEASE WITH REFERENCE TO CLINICAL PARAMETERS

Assessment of Su-i-Mizaj in the Patients of Non Alcoholic Fatty Liver Disease with reference to Clinical Parameters. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089473
Enrollment
99
Registered
2025-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Department Of Ilmul Amraz fO Unani Medicine AMU Aligarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically and laboratory diagnosed patients of fatty liver by ultrasound (up to grade II) will be included. Patients having a BMI of more than or equal to 25 Non- alcoholic Fatty Liver on the basis of history. LFT: AST (30-120 U/L), ALT (30-100 U/L ), Serum Alkaline phosphatase (140-300U/L). Lipid profile: LDL- cholesterol level: 130-159 mg/dl, Triglyceride:150-250 mg/dl,HDL less than 40 mg/dl in men 50 mg/dl in Women.total Cholesterol: 200-300 mg/ dl (According to NCEP, Adult Treatment Panel III, 2001), Pre-diabetic patients, controlled type II diabetic patients with HBA1C less than 8%, Controlled hypertensive patients who are on Antihypertensive treatment (120/80 mmHg- 159/99 mmHg) Willingness to sign the informed consent, follow the protocol.

Exclusion criteria

Exclusion criteria: Non Alcoholic fatty liver Grade III by ultrasound will be excluded. Alanine Aminotransferase (ALT) and/ Or Aspartate Aminotransferase (AST) more than 2 times the upper limit of normal. Patients having serum LDL- Cholesterol more than 160 mg/dl Triglycerides level more than 250 mg/dl total cholesterol level more than 300 mg/dl. Patients having BMI less than 25. Uncontrolled hypertension (Blood pressure more than 160/100 mmHg) Uncontrolled diabetes Mellitus (HBA1C more than 8%), Patients with the history of jaundice & other liver disease, cirrhosis of liver. Pregnant and lactating woman Patients with the history of other systemic disease like gastrointestinal disease, CVD, renal disease. Patients unwilling to give informed consent.

Design outcomes

Primary

MeasureTime frame
ASSESSMENT OF SU-I-MIZAJ IN NON ALCOHOLIC FATTY LIVER DISEASETimepoint: ONCE—

Secondary

MeasureTime frame
VALIDATION OF QUESTIONNAIRETimepoint: ONCE—

Countries

India

Contacts

Public ContactSalma Sultana

Ajmal Khan Tibbiya College And Hospital Aligarh Muslim University, Aligarh

drsmahmer@gmail.com9634368815

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026